

Inge Marie Svane

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6917946/publications.pdf>

Version: 2024-02-01

176
papers

8,997
citations

53794

45
h-index

56724

83
g-index

184
all docs

184
docs citations

184
times ranked

12403
citing authors

#	ARTICLE	IF	CITATIONS
1	Tertiary lymphoid structures improve immunotherapy and survival in melanoma. <i>Nature</i> , 2020, 577, 561-565.	27.8	1,209
2	Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 611-622.	10.7	428
3	Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma. <i>Nature Communications</i> , 2017, 8, 1738.	12.8	310
4	Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy. <i>JAMA Oncology</i> , 2019, 5, 187.	7.1	295
5	Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes. <i>Nature Biotechnology</i> , 2016, 34, 1037-1045.	17.5	279
6	Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 867-875.	1.6	258
7	Dabrafenib, trametinib and pembrolizumab or placebo in <i>BRAF</i> -mutant melanoma. <i>Nature Medicine</i> , 2019, 25, 941-946.	30.7	256
8	Collagen density regulates the activity of tumor-infiltrating T cells. , 2019, 7, 68.		239
9	Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen. <i>Clinical Cancer Research</i> , 2016, 22, 3734-3745.	7.0	234
10	Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1. <i>Nature Immunology</i> , 2020, 21, 178-185.	14.5	186
11	Principles of adoptive T cell therapy in cancer. <i>Seminars in Immunopathology</i> , 2019, 41, 49-58.	6.1	141
12	Dissection of T-cell Antigen Specificity in Human Melanoma. <i>Cancer Research</i> , 2012, 72, 1642-1650.	0.9	137
13	Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. <i>Journal of Translational Medicine</i> , 2012, 10, 169.	4.4	134
14	Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model. <i>Nature Communications</i> , 2017, 8, 707.	12.8	123
15	Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase. <i>Clinical Cancer Research</i> , 2014, 20, 221-232.	7.0	118
16	KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i> -mutant melanoma. , 2020, 8, e001806.		110
17	More tricks with tetramers: a practical guide to staining T cells with peptide-MHC multimers. <i>Immunology</i> , 2015, 146, 11-22.	4.4	106
18	Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1791-1804.	4.2	103

#	ARTICLE	IF	CITATIONS
19	The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study. <i>European Heart Journal</i> , 2021, 42, 1621-1631.	2.2	102
20	Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. <i>Blood</i> , 2011, 117, 2200-2210.	1.4	101
21	Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 633-641.	4.2	100
22	Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity. <i>Cancer Research</i> , 2015, 75, 3747-3759.	0.9	93
23	A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma. <i>Nature Medicine</i> , 2021, 27, 2212-2223.	30.7	88
24	Peptide-MHC Class I Tetramers Can Fail To Detect Relevant Functional T Cell Clonotypes and Underestimate Antigen-Reactive T Cell Populations. <i>Journal of Immunology</i> , 2018, 200, 2263-2279.	0.8	87
25	Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1485-1499.	4.2	85
26	HER2 CART-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice. <i>Cancer Research</i> , 2019, 79, 899-904.	0.9	84
27	BRAF inhibition improves tumor recognition by the immune system. <i>Oncolmmunology</i> , 2012, 1, 1476-1483.	4.6	82
28	Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study. <i>Oncolmmunology</i> , 2018, 7, e1502905.	4.6	80
29	HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer Patients. <i>Cancer Research</i> , 2013, 73, 1764-1776.	0.9	78
30	The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials. <i>European Journal of Cancer</i> , 2017, 74, 89-95.	2.8	77
31	Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab. <i>Oncolmmunology</i> , 2016, 5, e1100788.	4.6	73
32	Empty peptide-receptive MHC class I molecules for efficient detection of antigen-specific T cells. <i>Science Immunology</i> , 2019, 4, .	11.9	64
33	The Immune System Strikes Back: Cellular Immune Responses against Indoleamine 2,3-dioxygenase. <i>PLoS ONE</i> , 2009, 4, e6910.	2.5	64
34	Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer. <i>Oncotarget</i> , 2020, 11, 2092-2105.	1.8	64
35	Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. <i>Cancer Cell</i> , 2021, 39, 1623-1642.e20.	16.8	64
36	Chemically induced sarcomas from nude mice are more immunogenic than similar sarcomas from congenic normal mice. <i>European Journal of Immunology</i> , 1996, 26, 1844-1850.	2.9	62

#	ARTICLE	IF	CITATIONS
37	Escape from nonsense-mediated decay associates with anti-tumor immunogenicity. <i>Nature Communications</i> , 2020, 11, 3800.	12.8	61
38	T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma—Implications for Adoptive Cell Therapy. <i>Cancer Immunology Research</i> , 2018, 6, 222-235.	3.4	59
39	Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study. <i>Cytotherapy</i> , 2017, 19, 500-513.	0.7	58
40	Late development of splenic sarcoidosis-like lesions in a patient with metastatic melanoma and long-lasting clinical response to ipilimumab. <i>OncImmunity</i> , 2014, 3, e954506.	4.6	56
41	CCL22-specific T Cells: Modulating the immunosuppressive tumor microenvironment. <i>OncImmunity</i> , 2016, 5, e1238541.	4.6	56
42	Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 1341-1346.	4.2	55
43	Antibody Stabilization of Peptide-MHC Multimers Reveals Functional T Cells Bearing Extremely Low-Affinity TCRs. <i>Journal of Immunology</i> , 2015, 194, 463-474.	0.8	55
44	Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 2790-2795.	3.3	54
45	Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	54
46	PD-1+ Polyfunctional T Cells Dominate the Periphery after Tumor-Infiltrating Lymphocyte Therapy for Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5779-5788.	7.0	53
47	Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients. , 2018, 6, 152.		53
48	The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4 ⁺ T cells. <i>OncImmunity</i> , 2013, 2, e23991.	4.6	52
49	CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ tumor-infiltrating lymphocytes in ovarian cancer. <i>Scientific Reports</i> , 2020, 10, 3914.	3.3	50
50	Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care?. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 1081-1091.	4.2	48
51	Simplified protocol for clinical-grade tumor-infiltrating lymphocyte manufacturing with use of the Wave bioreactor. <i>Cytotherapy</i> , 2014, 16, 1117-1120.	0.7	47
52	The real-world impact of modern treatments on the survival of patients with metastatic melanoma. <i>European Journal of Cancer</i> , 2019, 108, 25-32.	2.8	47
53	Spontaneous Cytotoxic T-Cell Reactivity against Indoleamine 2,3-Dioxygenase-2. <i>Cancer Research</i> , 2011, 71, 2038-2044.	0.9	45
54	Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab. <i>Cytotherapy</i> , 2016, 18, 1043-1055.	0.7	45

#	ARTICLE	IF	CITATIONS
55	Tumour-reactive T cell subsets in the microenvironment of ovarian cancer. <i>British Journal of Cancer</i> , 2019, 120, 424-434.	6.4	44
56	Natural CD4+ T-Cell Responses against Indoleamine 2,3-Dioxygenase. <i>PLoS ONE</i> , 2012, 7, e34568.	2.5	43
57	Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab. <i>Oncolimmunology</i> , 2018, 7, e1424674.	4.6	43
58	Clinical application of dendritic cells in cancer vaccination therapy. <i>Apmis</i> , 2003, 111, 818-834.	2.0	41
59	High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 395-406.	2.5	41
60	Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer. <i>Cytotherapy</i> , 2011, 13, 822-834.	0.7	39
61	Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFN γ Signaling. <i>Cancer Research</i> , 2017, 77, 4562-4566.	0.9	39
62	Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma. , 2020, 8, e000391.		39
63	B Cells and Tertiary Lymphoid Structures: Friends or Foes in Cancer Immunotherapy?. <i>Clinical Cancer Research</i> , 2022, 28, 1751-1758.	7.0	39
64	Durable Clinical Responses and Long-Term Follow-Up of Stage IIIâ€“IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Studyâ€”A Brief Research Report. <i>Frontiers in Immunology</i> , 2018, 9, 2145.	4.8	37
65	Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma. <i>Cancers</i> , 2019, 11, 1489.	3.7	37
66	Differential effects of corticosteroids and antiâ€”TNF on tumorâ€”specific immune responses: implications for the management of irAEs. <i>International Journal of Cancer</i> , 2019, 145, 1408-1413.	5.1	36
67	Methylcholanthreneâ€”induced sarcomas in nude mice have short induction times and relatively low levels of surface MHC class I expression. <i>Apmis</i> , 1996, 104, 629-639.	2.0	35
68	PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine. <i>Oncolimmunology</i> , 2016, 5, e1202391.	4.6	33
69	The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy. <i>Oncolimmunology</i> , 2018, 7, e1390641.	4.6	33
70	Granzyme B Degraded Type IV Collagen Products in Serum Identify Melanoma Patients Responding to Immune Checkpoint Blockade. <i>Cancers</i> , 2020, 12, 2786.	3.7	32
71	Cancer immunotherapy in patients with preexisting autoimmune disorders. <i>Seminars in Immunopathology</i> , 2017, 39, 333-337.	6.1	31
72	Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma. , 2020, 8, e000668.		31

#	ARTICLE	IF	CITATIONS
73	Interferon γ induces marked alterations in circulating regulatory T cells, NK cell subsets, and dendritic cells in patients with JAK2V617F -positive essential thrombocythemia and polycythemia vera. <i>European Journal of Haematology</i> , 2016, 97, 83-92.	2.2	30
74	Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response. <i>Oncolmmunology</i> , 2018, 7, e1433521.	4.6	30
75	mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma. <i>Oncolmmunology</i> , 2016, 5, e1207842.	4.6	29
76	Cutaneous adverse reactions to anti-PD-1 treatment: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1415-1424.	1.2	29
77	Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms. <i>Frontiers in Oncology</i> , 2021, 11, 637420.	2.8	29
78	Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC). <i>Journal of Clinical Oncology</i> , 2022, 40, 3180-3189.	1.6	29
79	Frequent adaptive immune responses against arginase-1. <i>Oncolmmunology</i> , 2018, 7, e1404215.	4.6	27
80	Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma. <i>European Journal of Cancer</i> , 2019, 119, 122-131.	2.8	27
81	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations. <i>Frontiers in Immunology</i> , 2020, 11, 373.	4.8	27
82	Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma. <i>Oncotarget</i> , 2017, 8, 27062-27074.	1.8	26
83	Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2. <i>Vaccine</i> , 2008, 26, 4716-4724.	3.8	25
84	Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients. <i>Oncolmmunology</i> , 2013, 2, e23288.	4.6	25
85	Characterization of risk factors and efficacy of medical management of immune-related hepatotoxicity in real-world patients with metastatic melanoma treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2020, 130, 211-218.	2.8	23
86	Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types. , 2021, 9, e003499.		23
87	Indoleamine 2,3-dioxygenase and survivin peptide vaccine combined with temozolomide in metastatic melanoma. <i>Stem Cell Investigation</i> , 2017, 4, 77-77.	3.0	22
88	Design and validation of conditional ligands for $\text{HLA-B}^*08:01$, $\text{HLA-B}^*15:01$, $\text{HLA-B}^*35:01$, and $\text{HLA-B}^*44:05$. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2015, 87, 967-975.	1.5	21
89	The Danish metastatic melanoma database (DAMMED): A nation-wide platform for quality assurance and research in real-world data on medical therapy in Danish melanoma patients. <i>Cancer Epidemiology</i> , 2021, 73, 101943.	1.9	21
90	Indoleamine 2,3-dioxygenase vaccination. <i>Oncolmmunology</i> , 2015, 4, e983770.	4.6	20

#	ARTICLE	IF	CITATIONS
91	The controversial role of TNF in melanoma. <i>Oncolmmunology</i> , 2016, 5, e1107699.	4.6	20
92	Long-Term Exposure to Inflammation Induces Differential Cytokine Patterns and Apoptosis in Dendritic Cells. <i>Frontiers in Immunology</i> , 2019, 10, 2702.	4.8	20
93	T-Cell Gene Therapy in Cancer Immunotherapy: Why It Is No Longer Just CARs on The Road. <i>Cells</i> , 2020, 9, 1588.	4.1	20
94	Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies. <i>Frontiers in Immunology</i> , 2018, 9, 2264.	4.8	19
95	Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8+ T Cells in Non-Melanoma Cancers Compared to Melanoma. <i>Cancers</i> , 2020, 12, 3344.	3.7	19
96	Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer. <i>Cancers</i> , 2020, 12, 3828.	3.7	19
97	Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2021, 158, 156-168.	2.8	19
98	Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 417-428.	4.4	19
99	Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 627-641.	3.1	19
100	Autocrine CCL19 blocks dendritic cell migration toward weak gradients of CCL21. <i>Cytotherapy</i> , 2016, 18, 1187-1196.	0.7	18
101	Peptide Super-Agonist Enhances T-Cell Responses to Melanoma. <i>Frontiers in Immunology</i> , 2019, 10, 319.	4.8	18
102	The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines. <i>Oncolmmunology</i> , 2020, 9, 1771142.	4.6	18
103	Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF [®] 09b, in patients with metastatic melanoma. <i>Oncolmmunology</i> , 2022, 11, 2023255.	4.6	18
104	The Danish Melanoma Database. <i>Clinical Epidemiology</i> , 2016, Volume 8, 543-548.	3.0	17
105	Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial. <i>Frontiers in Immunology</i> , 2020, 11, 595035.	4.8	17
106	Immune Cell Profiling of Peripheral Blood as Signature for Response During Checkpoint Inhibition Across Cancer Types. <i>Frontiers in Oncology</i> , 2021, 11, 558248.	2.8	17
107	Peptide vaccination against multiple myeloma using peptides derived from anti-apoptotic proteins: a phase I trial. <i>Stem Cell Investigation</i> , 2016, 3, 95-95.	3.0	16
108	Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1901-1907.	4.2	16

#	ARTICLE	IF	CITATIONS
109	In vitro 4-1BB stimulation promotes expansion of CD8+ tumor-infiltrating lymphocytes from various sarcoma subtypes. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2179-2191.	4.2	16
110	Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS9605-TPS9605.	1.6	16
111	Spontaneous T-cell responses against peptides derived from the Taxol resistance-associated gene-3 (TRAG-3) protein in cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 219-228.	4.2	15
112	Cancer immunotherapy in patients with brain metastases. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 703-711.	4.2	15
113	Sorted peripheral blood cells identify <i>CALR</i> mutations in B- and T-lymphocytes. <i>Leukemia and Lymphoma</i> , 2018, 59, 973-977.	1.3	15
114	Genetic Biomarkers in Melanoma of the Ocular Region: What the Medical Oncologist Should Know. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5231.	4.1	15
115	Expression of β_2 -microglobulin by premalignant epithelium. <i>Apmis</i> , 1993, 101, 529-536.	2.0	14
116	Predictors of Chemotherapy-Induced Toxicity and Treatment Outcomes in Elderly Versus Younger Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e559-e568.	1.9	14
117	Immunoprofiles of colorectal cancer from Lynch syndrome. <i>Oncolmmunology</i> , 2019, 8, e1515612.	4.6	14
118	Peripheral memory T cells specific for Arginase-1. <i>Cellular and Molecular Immunology</i> , 2019, 16, 718-719.	10.5	13
119	FDG PET scans as evaluation of clinical response to dendritic cell vaccination in patients with malignant melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 17-25.	4.2	12
120	Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 204.	5.4	12
121	Low-dose prednisolone in first-line docetaxel for patients with metastatic castration-resistant prostate cancer: Is there a clinical benefit?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 494.e15-494.e20.	1.6	11
122	Transfection of Tumor-Infiltrating T Cells with mRNA Encoding CXCR2. <i>Methods in Molecular Biology</i> , 2016, 1428, 261-276.	0.9	11
123	High-dose interleukin-2 and interferon as first-line immunotherapy for metastatic melanoma: long-term follow-up in a large unselected Danish patient cohort. <i>European Journal of Cancer</i> , 2019, 115, 61-67.	2.8	11
124	Cytotoxic T cells isolated from healthy donors and cancer patients kill TGF β -expressing cancer cells in a TGF β -dependent manner. <i>Cellular and Molecular Immunology</i> , 2021, 18, 415-426.	10.5	10
125	Lynch syndrome-associated epithelial ovarian cancer and its immunological profile. <i>Gynecologic Oncology</i> , 2021, 162, 686-693.	1.4	10
126	Rapid Identification of the Tumor-Specific Reactive TIL Repertoire via Combined Detection of CD137, TNF, and IFN γ , Following Recognition of Autologous Tumor-Antigens. <i>Frontiers in Immunology</i> , 2021, 12, 705422.	4.8	10

#	ARTICLE	IF	CITATIONS
127	T cell recognition of novel shared breast cancer antigens is frequently observed in peripheral blood of breast cancer patients. <i>Onc Immunology</i> , 2019, 8, e1663107.	4.6	9
128	Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome. <i>Cytotherapy</i> , 2020, 22, 204-213.	0.7	9
129	Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma. , 2021, 9, e002703.		9
130	ACT Up TIL Now: The Evolution of Tumor-Infiltrating Lymphocytes in Adoptive Cell Therapy for the Treatment of Solid Tumors. <i>Immuno</i> , 2021, 1, 194-211.	1.5	9
131	Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment. <i>Onc Immunology</i> , 2022, 11, 2026020.	4.6	9
132	Improved Progression-Free Long-Term Survival of a Nation-Wide Patient Population with Metastatic Melanoma. <i>Cancers</i> , 2020, 12, 2591.	3.7	8
133	The effects of targeted immune-regulatory strategies on tumor-specific T-cell responses in vitro. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1771-1776.	4.2	8
134	Epigenetic therapy in combination with a multi-epitope cancer vaccine targeting shared tumor antigens for high-risk myelodysplastic syndrome—A phase I clinical trial. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 433-444.	4.2	8
135	Vaccination against PD-L1 with IO103 a Novel Immune Modulatory Vaccine in Basal Cell Carcinoma: A Phase IIa Study. <i>Cancers</i> , 2021, 13, 911.	3.7	7
136	B cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: Influence of ruxolitinib, interferon- γ , or combination treatment. <i>European Journal of Haematology</i> , 2019, 103, 351-361.	2.2	6
137	The capacity of CD4+ V β 9V α 2 T cells to kill cancer cells correlates with co-expression of CD56. <i>Cytotherapy</i> , 2021, 23, 582-589.	0.7	6
138	Transcriptomic signatures of tumors undergoing T cell attack. <i>Cancer Immunology, Immunotherapy</i> , 2021, , 1.	4.2	6
139	Combination immunotherapy with IDO vaccine and PD-1 inhibitors in advanced NSCLC.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS2610-TPS2610.	1.6	6
140	Laser Immunotherapy: A Potential Treatment Modality for Keratinocyte Carcinoma. <i>Cancers</i> , 2021, 13, 5405.	3.7	6
141	Pembrolizumab (pembro) plus dabrafenib (dab) and trametinib (tram) in BRAF ^{V600E/K} -mutant melanoma: Long-term follow-up of KEYNOTE-022 parts 1, 2, and 3.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9516-9516.	1.6	6
142	Clinical Impact of the Number of Treatment Cycles in First-Line Docetaxel for Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e281-e287.	1.9	5
143	An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphoma. <i>Onc Immunology</i> , 2021, 10, .	4.6	5
144	Bone marrow toxicity and immune reconstitution in melanoma and non-melanoma solid cancer patients after non-myeloablative conditioning with chemotherapy and checkpoint inhibition. <i>Cytotherapy</i> , 2021, 23, 724-729.	0.7	5

#	ARTICLE	IF	CITATIONS
145	Clinical value of routine [¹⁸ F]2- ¹⁸ F-fluoro-2-deoxy- ¹⁸ F-glucose positron emission tomography scans as a decision tool for early immunotherapy discontinuation in advanced melanoma. <i>International Journal of Cancer</i> , 2022, 150, 1870-1878.	5.1	5
146	EMRseq: Registry-based outcome analysis on 1,000 patients with BRAF V600E-mutated metastatic melanoma in Europe treated with either immune checkpoint or BRAF-/MEK inhibition.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9540-9540.	1.6	5
147	Spontaneous presence of FOXO3-specific T cells in cancer patients. <i>OncImmunity</i> , 2014, 3, e953411.	4.6	4
148	Immune check point inhibitors are associated with a spectrum of cardiac events in patients with cancer. <i>European Heart Journal</i> , 2021, 42, 1636-1636.	2.2	4
149	Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9500-9500.	1.6	4
150	Real life outcome of advanced melanoma patients who discontinue pembrolizumab (PEMBRO) in the absence of disease progression.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9539-9539.	1.6	4
151	Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study. <i>Cancers</i> , 2021, 13, 5550.	3.7	4
152	Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st-2nd, 2021. <i>Journal of Translational Medicine</i> , 2022, 20, .	4.4	4
153	LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes in patients with metastatic soft tissue sarcoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 11567-11567.	1.6	4
154	Immune Monitoring Using mRNA-Transfected Dendritic Cells. <i>Methods in Molecular Biology</i> , 2016, 1428, 245-259.	0.9	3
155	Cardiotoxicity in metastatic melanoma patients treated with BRAF and MEK inhibitors in a real-world setting. <i>Acta Oncologica</i> , 2022, 61, 45-51.	1.8	3
156	High MHC class I expression correlates with slow growth in UVB-induced skin carcinomas in hairless mice. <i>Apmis</i> , 1998, 106, 1101-1107.	2.0	2
157	Characterization of Spontaneous Immune Responses against Long Peptides Derived from Bcl-X(L) in Cancer Patients Using Elispot. <i>Cells</i> , 2012, 1, 51-60.	4.1	2
158	Adoptive T-cell therapy (ACT) with TILs for metastatic melanoma: Clinical responses and durable persistence of anticancer responses in peripheral blood.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3028-3028.	1.6	2
159	Effects of ipilimumab on expanded tumor-infiltrating lymphocytes in patients with stage IV malignant melanoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3020-3020.	1.6	2
160	Therapeutic Cancer Vaccination Targeting Shared Tumor Associated Antigens in Combination with Azacitidine for High Risk Myelodysplastic Syndrome - a Phase I Clinical Trial. <i>Blood</i> , 2020, 136, 23-24.	1.4	2
161	Immune Checkpoint Inhibitor Treatment and Ophthalmologist Consultations in Patients with Malignant Melanoma or Lung Cancer- A Nationwide Cohort Study. <i>Cancers</i> , 2022, 14, 49.	3.7	2
162	Large-Scale mRNA Transfection of Dendritic Cells by Electroporation in Continuous Flow Systems. <i>Methods in Molecular Biology</i> , 2016, 1428, 151-161.	0.9	1

#	ARTICLE	IF	CITATIONS
163	Randomized phase 2 study of nivolumab with or without ipilimumab in combination with stereotactic body radiotherapy in patients with refractory metastatic pancreatic cancer (CHECKPAC).. Journal of Clinical Oncology, 2022, 40, 554-554.	1.6	1
164	Abstract CT535: High clinical efficacy in poor prognosis patients with metastatic melanoma treated with an IDO/PD-L1 peptide vaccine in combination with nivolumab. Cancer Research, 2022, 82, CT535-CT535.	0.9	1
165	First-in-human clinical trial of an oncolytic adenovirus armed with TNF α and IL-2 in patients with advanced melanoma receiving adoptive cell transfer of tumor-infiltrating lymphocytes.. Journal of Clinical Oncology, 2022, 40, TPS9590-TPS9590.	1.6	1
166	Comment on "Adoptive T-cell therapy for malignant melanoma patients with TILs obtained by ultrasound-guided needle biopsy" by Gustav J. Ullenhag et al.. Cancer Immunology, Immunotherapy, 2012, 61, 747-747.	4.2	0
167	ATIM-01. NIVOLUMAB AND BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA; A TRANSLATIONAL TRIAL IN PROGRESS. Neuro-Oncology, 2019, 21, vi1-vi1.	1.2	0
168	Phase I study of peptide vaccine targeting indoleamine 2,3 dioxygenase in metastatic lung cancer patients.. Journal of Clinical Oncology, 2013, 31, 8084-8084.	1.6	0
169	PD-L1 specific tumor infiltrating lymphocytes occur frequently in melanoma and HNSCC patients.. Journal of Clinical Oncology, 2014, 32, 11083-11083.	1.6	0
170	Preclinical development of tumor-infiltrating lymphocyte (TIL) based adoptive cell transfer (ACT) immunotherapy for patients with sarcoma and the potential benefit of anti-CD137 stimulation.. Journal of Clinical Oncology, 2017, 35, e14545-e14545.	1.6	0
171	Assessment of extracellular matrix and tissue derived metabolites in a liquid biopsy for identifying endotypes of metastatic melanoma patients with differential response to immune checkpoint inhibitor treatment.. Journal of Clinical Oncology, 2019, 37, e14050-e14050.	1.6	0
172	CTIM-22. NIVOLUMAB AND BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA; T-CELL REACTIVITY AGAINST AUTOLOGOUS TUMOR CELLS. Neuro-Oncology, 2021, 23, vi54-vi55.	1.2	0
173	CTIM-23. EVIDENCE OF T CELL ACTIVATION AND INTRATUMORAL NIVOLUMAB-PRESENCE IN GLIOBLASTOMA PATIENTS TREATED WITH NIVOLUMAB AND BEVACIZUMAB. Neuro-Oncology, 2021, 23, vi55-vi55.	1.2	0
174	Immune selection in murine tumors. Ph.d thesis. Acta Pathologica Microbiologica Et Immunologica Scandinavica - Supplementum, 2003, , 1-46.	0.2	0
175	Indirect assessment of tumor-infiltrating lymphocyte activity in serum for predicting outcome in patients with glioblastoma treated with immunotherapy in the recurrent setting.. Journal of Clinical Oncology, 2022, 40, 2059-2059.	1.6	0
176	Randomized phase 3 trial of IO102-IO103 plus pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic melanoma.. Journal of Clinical Oncology, 2022, 40, TPS9589-TPS9589.	1.6	0